Immatics Presenting at BioInsight’s Cell & Gene Therapy Live Webinar
Jul 14, 2020 at 11:00 AM EDT
Join us on July 14 for Bioinsight’s Cell & Gene Therapy live webinar dedicated to bringing you the latest cutting-edge research and commentary in bioscience!
E-meet Ali Mohamed for his presentation and engage in the following discussion about Immatics’ ACTolog® concept and data from the IMA101-101 trial:
Tuesday, July 14, 8am PDT (11am EDT/ 4pm BST/ 5pm CEST)
Presentation: Manufacturing of endogenous, non-engineered, antigen specific T cells against tumor targets
•Which manufacturing steps are critical in achieving a successful manufacturing of autologous antigen specific T cells?
•What are the differences between endogenous antigen-specific T cell products and engineered T cells (e.g. classical CAR or TCR-T cells)?
•How can multiparametric and closed system cell sorting be utilized in clinical application?
•How do standardization tools help achieve reproducible QC/IPC of cellular products?
And afterwards don’t miss to discuss:
•The ACTolog® concept – Immatics’ ultra-personalized, multi-target immunotherapy pilot program; including the priming, isolation, sorting, and expansion of target-specific T cells
•The exemplary manufacturing and clinical data from the IMA101-101 trial utilizing ACTolog®
•The insights into the effective application of the MACSQuant® Tyto® Cell Sorter for T cell sorting
•The utility of novel tools for the facilitation of reproducible flow cytometry-based IPC/QC processes
We are looking forward to e-meeting you!
Learn more about the Cell & Gene Therapy Insights here.